Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company pioneering novel therapies for multidrug-resistant bacterial infections and rare diseases. This page serves as the definitive source for verified news and official updates on SPRO's research advancements, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely updates on key programs including tebipenem HBr (oral carbapenem antibiotic), SPR206 (IV polymyxin), and other pipeline developments. The curated news collection covers clinical trial results, FDA communications, partnership announcements, and financial disclosures.
All content is rigorously verified to ensure accuracy and relevance for stakeholders monitoring antibiotic innovation. Bookmark this page for direct access to SPRO's latest developments in addressing critical unmet medical needs through advanced therapeutic candidates.
Spero Therapeutics, Inc. (Nasdaq: SPRO) reported its Q1 2021 financial results, showing a net loss of $19.4 million, improved from $23.3 million a year earlier. Total revenues surged to $7.3 million, up from $1.7 million, mainly due to a BARDA grant for tebipenem HBr. The company remains on track for an NDA submission of tebipenem HBr in H2 2021 after a successful pre-NDA meeting with the FDA. However, the Phase 2a trial of SPR720 is on hold due to non-human primate mortalities, leading to trial discontinuation while further data is analyzed.
Spero Therapeutics (Nasdaq: SPRO) announced the grant of non-qualified stock options to new employees, totaling 28,600 shares, as part of its 2019 Inducement Equity Incentive Plan. The stock options, awarded on April 30, 2021, have an exercise price of $13.76, equivalent to the closing price on that day. Each option will vest over four years, with 25% vesting after the first year. Spero focuses on developing treatments for multi-drug resistant infections and rare diseases, with its lead product candidate, tebipenem HBr, aimed at treating complicated urinary tract infections.
Spero Therapeutics (Nasdaq: SPRO) announced a conference call on May 6, 2021, at 4:30 p.m. ET to discuss its Q1 2021 financial results and provide a business update.
The company focuses on developing novel treatments for multi-drug-resistant infections and rare diseases, with its lead candidate, tebipenem HBr, showing positive Phase 3 trial results for complicated urinary tract infections. Spero is also developing SPR720 for orphan pulmonary diseases and SPR206 targeting MDR Gram-negative infections.
Spero Therapeutics announced on March 31, 2021, the grant of non-qualified stock options to purchase 22,050 shares of common stock as part of its 2019 Inducement Equity Incentive Plan. These options were awarded to three new employees to incentivize their employment with the company, complying with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $14.72 per share, equal to the stock's closing price on the same day. The options vest over four years, contingent on the employees' continued service.
Spero Therapeutics (Nasdaq: SPRO) reported its fourth quarter and full-year 2020 financial results, highlighting significant progress in its drug development programs amidst COVID-19 challenges. The company plans to submit a New Drug Application (NDA) for tebipenem HBr in the second half of 2021 after successful Phase 3 trial results. In 2020, Spero faced a net loss of $78.8 million on $9.3 million in revenue, down from $18.1 million in 2019. Notably, expenses in R&D decreased, but G&A expenses rose due to increased staffing. Spero has $126.9 million in cash reserves, expected to sustain operations into Q2 2022.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a conference call on March 11, 2021, at 4:30 p.m. EST to discuss its fourth quarter and full-year 2020 financial results as well as updates on its business and pipeline. The call will be accessible via phone or an audio webcast on the company’s website. Spero focuses on developing novel treatments for multi-drug-resistant bacterial infections and rare diseases, with key products including tebipenem HBr, a potential first oral carbapenem antibiotic for complicated urinary tract infections, and SPR720 for rare pulmonary diseases.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that its CEO, Ankit Mahadevia, M.D., will present at two upcoming investor conferences in March 2021. The events include the Cowen 41st Annual Healthcare Conference on March 1, and the Oppenheimer 31st Annual Healthcare Conference on March 16. The presentations will focus on Spero's development of treatments for multi-drug resistant bacterial infections and rare diseases, including its lead candidate, tebipenem HBr, aimed at treating complicated urinary tract infections.
Spero Therapeutics (Nasdaq: SPRO) announced a clinical hold on its Phase 2a trial of SPR720, an oral antimicrobial agent for nontuberculous mycobacterial pulmonary disease. This action follows a pause in dosing due to concerns raised by an ongoing animal toxicology study, which observed mortalities in non-human primates. No serious adverse events have been reported in human trials, and the FDA is in discussions with Spero to evaluate findings. SPR720 has the potential to offer a new treatment option for patients with this rare disease.
Spero Therapeutics (Nasdaq: SPRO) announced on January 29, 2021, that its Board of Directors granted stock option awards totaling 74,300 shares to six new employees. This grant, made under the 2019 Inducement Equity Incentive Plan, complies with Nasdaq Listing Rule 5635(c)(4). The options, priced at $18.11 per share, will vest over four years. Spero is focused on developing treatments for multi-drug resistant infections and rare diseases, with key products including tebipenem HBr for complicated urinary tract infections and SPR720 for non-tuberculous mycobacterial infections.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the issuance of U.S. Patent No. 10,889,587 for its oral carbapenem, tebipenem HBr, aimed at treating complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). This patent protects its formulation and expires in February 2038. The company previously reported positive results from its Phase 3 clinical trial of tebipenem HBr in September 2020. With Qualified Infectious Disease Product status and fast track designation from the FDA, Spero plans to submit a New Drug Application in the second half of 2021.
